Selecta Biosciences Inc. said it plans to raise up to $75 million in an initial public offering, according to a Securities and Exchange Commission filing late Tuesday. The Watertown, Mass.-based biotech uses synthetic vaccine nanoparticles to develop treatments for rare and serious diseases. Selecta reported $6 million in grant and collaboration revenue for a loss of $3.88 a share for 2015. The company plans to trade on the Nasdaq under the ticker “SELB”. UBS Investment Bank and Stifel are listed among underwriters for the IPO.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News